BDI Pharma, Inc, Canada's specialty biotech distributor, announced 25% monthly growth rate in its expansion into the animal health market.

4legPharma, the Animal Health Division of BDI Pharma, was launched in October, 2010 to provide veterinarians and veterinary specialists a safe and reliable resource for those specialty biopharmaceuticals used to treat pets suffering from many of the same chronic, life-threatening conditions affecting humans.

Building on a successful launch last fall, the company's recorded sales revenue and units sold for this unique market segment is trending well over 25% in monthly growth year to date. The veterinary customer base has grown by 127%.

"It appears that both our instincts and analysis were correct and the commitment of BDI resources in an effort to cater to the needs of the specialty veterinary marketplace has been well received," stated Angela Phillips, director of 4legPharma. "The response of the veterinary community has been extremely positive. We are now an active member of the AVDA, and have developed long-term business partnerships with several industry-leading companies that will bring innovative, cost-effective solutions to those caring for our companion animals."

BDI Pharma's portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or "hyper" immune globulins, and other specialty injectables. BDI Pharma is recognised as an "ADR," or Authorised Distributor of Record, for all of the manufacturers it represents.